Boehringer Ingelheim's "female Viagra" shows mixed results in Phase III
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim's once-daily 5-HT1A agonist and 5-HT2A antagonist flibanserin has demonstrated mixed results in four pivotal Phase III trials – DAISY, VIOLET, DAHLIA and ORCHID – examining the drug's effects on the number of satisfying sexual events (SSEs),sexual desire and the distress associated with hypoactive sexual desire disorder (HSDD) in pre-menopausal women.